NEW
YORK, June 7, 2023 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Reata
Pharmaceuticals, Inc.:
On May 10, 2023, Reata issued a
press release announcing its financial results for the first
quarter of 2023. Among other items, Reata announced its decision to
discontinue studies for its kidney disease candidate bardoxolone,
which the Company had previously advanced as one of its lead assets
in partnership with Blackstone Life Sciences and Kyoma Kirin. On
this news, Reata's stock price fell $14.99 per share or 14.23%, to close at
$90.38 per share on May 10, 2023.
Due to the forgoing, The Gross Law Firm is investigating
potential securities fraud claims on behalf of certain Reata
investors. If you incurred a loss on your RETA investment, please
contact us using the link below to discuss your rights.
https://securitiesclasslaw.com/securities/reata-loss-submission-form/?id=40412&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-reata-pharmaceuticals-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-reta-301844391.html
SOURCE The Gross Law Firm